Oncology Nurse Advisor

oncologynurseadv.bsky.social

15 July 2025 15:19

A real-time personalized algorithm may help to effectively plan HDMTX infusion among pediatric patients with acute #lymphoblasticLeukemia in non-optimal clinical settings. Published in @ascocancer.bsky.social journal JCO Global Oncology and @hematologyadvisor.bsky.social. bit.ly/3ZoFmy6 #leusm

Oncology Nurse Advisor

oncologynurseadv.bsky.social

15 July 2025 15:19

A pilot study involving the experiences of caregivers suggests that those caring for children with #sickleCellDisease had felt a greater sense of hope than did those caring for children with cancer. From @hematologyadvisor.bsky.social. bit.ly/43NGUED #SCD

Cancer Therapy Advisor

cancertherapyadv.bsky.social

11 June 2025 16:17

Adding lurbinectedin to atezolizumab as first-line maintenance improved PFS and OS in patients with ES-SCLC, according to results from the phase 3 IMforte trial presented at #ASCO25. #lcsm shorturl.at/MRY1E

American Society of Clinical Oncology

ascocancer.bsky.social

01 June 2025 19:29

Dr. Katherine Walsh points out the dramatic changes in phlebotomy independence and hematocrit control along with significant symptom reduction. #ASCO25

American Society of Clinical Oncology

ascocancer.bsky.social

01 June 2025 19:29

THIRD! Dr. Andrew Kuykendall presents VERIFY: rusfertide vs placebo for polycythemia vera. During weeks 20-32, more patients who received rusfertide achieved a clinical response, 76.9 vs 32.9%, p<0.0001. Patients received fewer phlebotomies and had less fatigue. #ASCO25